AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BridgeBio's Attruby Shows Significant Reduction in Cardiovascular Mortality in ATTR-CM Patients
ByAinvest
Saturday, Aug 30, 2025 11:05 am ET1min read
BridgeBio Pharma's Attruby (acoramidis) showed significant reduction in cardiovascular mortality in individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) in a new open-label study. At 42 months post-randomization, Attruby led to a 44% reduction.
BridgeBio Pharma's Attruby (acoramidis) has shown promising results in reducing cardiovascular mortality (CVM) among individuals with transthyretin amyloid cardiomyopathy (ATTR-CM) in a recent open-label study. The findings, presented at the European Society of Cardiology (ESC) Congress 2025 in Madrid, Spain, indicate a significant reduction in CVM through 42 months post-randomization [1].The study, part of the ATTRibute-CM open-label extension (OLE), demonstrated a 44% hazard reduction in CVM, setting a new standard for CVM outcomes in ATTR-CM patients. This reduction was observed in both ATTRv-CM (variant) and ATTRwt-CM (wild-type) patients, highlighting the drug's broad applicability [1].
Additionally, Attruby showed a 46% hazard reduction in the risk of the composite outcome of CVM or first cardiovascular hospitalization (CVH) through 42 months. The drug also demonstrated higher rates of disease stabilization or improvement versus disease progression, as reflected in changes from baseline in NT-proBNP and NAC Stage [1].
The study's results underscore the long-term clinical benefits of Attruby for reducing CVM in ATTR-CM patients, emphasizing the importance of early and sustained treatment. The drug has received approvals from the U.S. FDA as Attruby and the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency as BEYONTTRA [1].
BridgeBio Pharma, a biopharmaceutical company focused on genetic diseases, presented these findings. The company's pipeline includes several development programs ranging from early science to advanced clinical trials. BridgeBio was founded in 2015 and is committed to delivering transformative medicines to patients suffering from genetic diseases [2].
References:
[1] https://www.morningstar.com/news/globe-newswire/9520845/acoramidis-demonstrates-statistically-significant-reduction-in-cardiovascular-mortality-cvm-through-month-42-of-the-attribute-cm-open-label-extension
[2] https://www.bridgebio.com
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet